Enjoy complimentary customisation on priority with our Enterprise License!
The pneumococcal vaccine market size is forecast to increase by USD 2.85 billion at a CAGR of 5.6% between 2023 and 2028.
The pneumococcal vaccine industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The pneumococcal conjugate vaccine plays a crucial role in preventing infections caused by Streptococcus pneumoniae, a bacterium responsible for pneumonia, meningitis, and sepsis. This vaccine significantly reduces the incidence of pneumonia, particularly among children under five, who were previously at high risk of hospitalization and mortality due to this disease. The global implementation of immunization programs has led to a substantial decrease in pneumonia cases, hospitalizations, and mortality rates. Immunocompromised patients, geriatric population, and those with chronic conditions such as lung disease, chronic heart disease, diabetes, human immunodeficiency, and splenectomy are also at increased risk for pneumococcal diseases. Pneumococcal strains continue to evolve, necessitating ongoing research activities and pipeline studies.
The vaccine is administered through various routes, including intramuscular and intradermal injections, and is available at pharmacies, community clinics, and pediatric offices. Common side effects include redness, headache, tiredness, and generalized muscle pain. Protein-based vaccines are also under development to address the prominence of pneumococcal diseases. Despite the success of immunization programs, economic disparities and vaccine accessibility remain challenges.
Get a glance at the Pneumococcal Vaccine Industry report of share of various segments Request Free Sample
The Pneumococcal conjugate vaccine segment was valued at USD 6.71 billion in 2018 and showed a gradual increase during the forecast period.
Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
The market in North America has experienced significant growth due to the increasing prevalence of pneumococcal diseases, such as pneumonia, sepsis, and meningitis. According to the Centers for Disease Control and Prevention (CDC), approximately 150,000 cases of invasive pneumococcal disease and around 3250 deaths occur annually In the US. This highlights the importance of vaccination to protect individuals from Streptococcus pneumoniae, the bacteria responsible for these diseases. In North America, where healthcare infrastructure is well-established, efficient vaccine distribution and administration are facilitated. Immunization programs target various demographic groups, including the immunocompromised, geriatric population, and those with underlying conditions like chronic heart disease, diabetes, human immunodeficiency, and splenectomy.
Pneumococcal conjugate vaccines, given as booster doses, are administered via different routes, including intramuscular injections and intranasal sprays. Pharmacies and community clinics play a crucial role in vaccine accessibility. Despite the importance of these vaccines, economic disparities can impact vaccine accessibility. Novel protein-based vaccines are under pipeline study to enhance vaccine efficacy and reduce the burden of pneumococcal diseases.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Expanding immunization programs by government in developing countries is the key driver of the market.
Advancements in vaccine technologies is the upcoming market trend.
What challenges does the Pneumococcal Vaccine Industry face during its growth?
High cost of vaccine development and production is a key challenge affecting the industry growth.
Exclusive Customer Landscape
The pneumococcal vaccine market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the pneumococcal vaccine market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, pneumococcal vaccine market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.
Astellas Pharma Inc. - The company specializes in innovative pneumococcal vaccine technologies, including the Multiple Antigen Presenting System (MAPS). This approach advances the development of a novel vaccine to combat Streptococcus pneumoniae diseases, contributing to the prevention and reduction of their spread. The MAPS technology enhances vaccine efficacy by delivering antigens effectively to the immune system. This scientific advancement underscores the company's commitment to addressing global health challenges and improving public health through advanced vaccine solutions.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market represents a significant segment withIn the broader vaccines industry, driven by the persistent prevalence and burden of pneumococcal diseases. These conditions, which include pneumonia, meningitis, and sepsis, pose a substantial health threat, particularly among vulnerable populations such as the immunocompromised, geriatric population, and those with underlying health conditions like chronic heart disease, diabetes, human immunodeficiency, and splenectomy. Pneumococcal diseases are caused by the bacterium Streptococcus pneumoniae, which can affect various body systems, including the lungs, bloodstream, and brain covering. The bacteria can lead to contagious diseases like sinusitis and lung disease, and in severe cases, can result in hospitalizations and high mortality rates.
The prominence of pneumococcal diseases necessitates ongoing research activities and pipeline studies to develop effective vaccines and expand immunization programs. The vaccine market for pneumococcal diseases encompasses various types, including conjugate and protein-based vaccines, which offer protection against different strains of the bacteria. The demand for pneumococcal vaccines is influenced by several factors, including demographic trends, economic disparities, and vaccine accessibility. For instance, the geriatric population is at a higher risk for pneumococcal diseases due to age-related immune system decline. Additionally, economic disparities can limit access to vaccines for certain populations, exacerbating health disparities. The administration routes for pneumococcal vaccines vary, with options including pharmacies, community clinics, and pediatric settings.
These vaccines are typically administered as a series of doses, with a booster dose recommended for certain populations. Despite the availability of vaccines, challenges persist in ensuring adequate vaccine uptake and addressing vaccine hesitancy. Factors contributing to vaccine hesitancy include concerns about vaccine safety and efficacy, as well as logistical barriers to access. The market is subject to ongoing competition and innovation, with companies continually working to improve vaccine efficacy, safety, and accessibility. The development of novel pneumococcal vaccines and the expansion of immunization programs are expected to drive market growth In the coming years. In summary, the market is a critical component of the vaccines industry, addressing the health burden of pneumococcal diseases and offering protection against various strains of Streptococcus pneumoniae.
Market dynamics, including demographic trends, economic disparities, and vaccine accessibility, influence market growth and competition. Ongoing research and innovation are essential to addressing the evolving needs of the market and ensuring effective vaccine solutions for vulnerable populations.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
158 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.6% |
|
Market growth 2024-2028 |
USD 2845.2 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.2 |
|
Key countries |
US, Germany, UK, Canada, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
We can help! Our analysts can customize this pneumococcal vaccine market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
